BETHESDA 2014: WHY?
The past decade has witnessed several changes in the realm of cervical cancer screening, prevention, and management. These include the increased use of liquid-based preparations; the addition of cotesting (Pap and hrHPV testing) and, more recently, primary hrHPV testing as additional screening options; further insights into HPV biology; changes in histopathology terminology; approval and implementation of prophylactic HPV vaccines; and updated guidelines for cervical cancer screening and clinical management.
Ler o artigo completo aqui.
Article first published online: 1 MAY 2015
doi:10.1002/cncy.21521
Citation: [Nayar, R. and Wilbur, D. C. (2015), The Pap test and Bethesda 2014. Cancer Cytopathology, 123: 271–281. doi: 10.1002/cncy.21521] Copyright: © 2015 S. Karger AG, Basel.
From: US National Library of Medicine <http://www.nlm.nih.gov/> – National Institutes of Health <http://www.nih.gov/>
Disclaimer: http://www.ncbi.nlm.nih.gov/
